SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches

Caitlin R. Rausch; Hagop M. Kantarjian; Elias J. Jabbour

doi:10.1016/j.clml.2023.01.013

SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches

Caitlin R. Rausch, Hagop M. Kantarjian, Elias J. Jabbour

Leukemia

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Combination chemotherapy is the mainstay of treatment for acute lymphoblastic leukemia (ALL). The Hyper-CVAD regimen was developed in 1992 at MD Anderson Cancer Center and has since become a standard of care option for adult patients with ALL. Since its conception, a number of modifications have been implemented to customize the regimen for different patient populations and safely incorporate novel therapies without compromising tolerability. We aim to review the evolution of the Hyper-CVAD regimen over the past 3 decades, focusing on clinical pearls, as well as future directions.

Original language	English (US)
Pages (from-to)	238-243
Number of pages	6
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	23
Issue number	4
DOIs	https://doi.org/10.1016/j.clml.2023.01.013
State	Published - Apr 2023

Keywords

ALL
Blinatumomab
Hyper-CVAD
Inotuzumab
Update

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2023.01.013

Cite this

@article{cd594764ba6442d1b8b543f3cd3cfb6e,

title = "SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches",

abstract = "Combination chemotherapy is the mainstay of treatment for acute lymphoblastic leukemia (ALL). The Hyper-CVAD regimen was developed in 1992 at MD Anderson Cancer Center and has since become a standard of care option for adult patients with ALL. Since its conception, a number of modifications have been implemented to customize the regimen for different patient populations and safely incorporate novel therapies without compromising tolerability. We aim to review the evolution of the Hyper-CVAD regimen over the past 3 decades, focusing on clinical pearls, as well as future directions.",

keywords = "ALL, Blinatumomab, Hyper-CVAD, Inotuzumab, Update",

author = "Rausch, {Caitlin R.} and Kantarjian, {Hagop M.} and Jabbour, {Elias J.}",

note = "Funding Information: No financial support was used in the creation of this manuscript. Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = apr,

doi = "10.1016/j.clml.2023.01.013",

language = "English (US)",

volume = "23",

pages = "238--243",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "4",

}

TY - JOUR

T1 - SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022

T2 - Lessons Learned and New Approaches

AU - Rausch, Caitlin R.

AU - Kantarjian, Hagop M.

AU - Jabbour, Elias J.

PY - 2023/4

Y1 - 2023/4

N2 - Combination chemotherapy is the mainstay of treatment for acute lymphoblastic leukemia (ALL). The Hyper-CVAD regimen was developed in 1992 at MD Anderson Cancer Center and has since become a standard of care option for adult patients with ALL. Since its conception, a number of modifications have been implemented to customize the regimen for different patient populations and safely incorporate novel therapies without compromising tolerability. We aim to review the evolution of the Hyper-CVAD regimen over the past 3 decades, focusing on clinical pearls, as well as future directions.

AB - Combination chemotherapy is the mainstay of treatment for acute lymphoblastic leukemia (ALL). The Hyper-CVAD regimen was developed in 1992 at MD Anderson Cancer Center and has since become a standard of care option for adult patients with ALL. Since its conception, a number of modifications have been implemented to customize the regimen for different patient populations and safely incorporate novel therapies without compromising tolerability. We aim to review the evolution of the Hyper-CVAD regimen over the past 3 decades, focusing on clinical pearls, as well as future directions.

KW - ALL

KW - Blinatumomab

KW - Hyper-CVAD

KW - Inotuzumab

KW - Update

UR - http://www.scopus.com/inward/record.url?scp=85149648929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85149648929&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2023.01.013

DO - 10.1016/j.clml.2023.01.013

M3 - Review article

C2 - 36872149

AN - SCOPUS:85149648929

SN - 2152-2650

VL - 23

SP - 238

EP - 243

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 4

ER -

SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this